INS and Hypoglycemia: It should be noted that outcomes documenting lactoprivic augmentation of the gluco-inhibitory transmitter GABA likely reflect, to some extent, differences associated with this experimental model (which involves selective pharmacological activation of a single metabolic-sensory cell population, e.g., hindbrain A2 neurons) compared with systemic insulin-induced hypoglycemia (which is characterized by body-wide sensor activation).